Bullous Keratopathy Market Snapshot (2023 to 2033)
The global bullous keratopathy market was valued at US$ 410 Million in 2022. By 2023, the market is forecast to reach a valuation of US$ 427.54 Million. During the 2023 to 2033 assessment period, a CAGR of 4.3% is anticipated, with an anticipated closing value of US$ 650 Million.
Bullous keratopathies are much less common than they used to be as surgery techniques and implants have enhanced. Complications from cataract surgery used to be the most common cause of bullous keratopathy. Currently, the most common cause of bullous keratopathy is complications due to glaucoma surgery.
Occasionally, bullous keratopathy may be caused by corneal dystrophy. Corneal dystrophies are a group of genetic conditions that result in abnormal material accumulating within the cornea. Rarely, a few other eye conditions or blunt-force trauma to the eye can result in bullous keratopathy.
The ultimate method of curing bullous keratopathy is a corneal transplant. A corneal transplant replaces the affected cornea with a donor. This may include transplant techniques such as a penetrating keratoplasty to replace the entire cornea, a Descemet Stripping Endothelial Keratoplasty (DSEK), Descemet Stripping Automated Endothelial Keratoplasty (DSAEK), or Descemet Membrane Endothelial Keratoplasty (DMEK) to replace the just the Descemet membrane.
Bullous keratopathy has many treatment options including both medicinal and surgical. Medical management options for bullous keratopathy include lubricants, steroids, hyperosmotic agents in the form of sodium chloride drops and ointment, anti-glaucoma drugs, and antibiotics. Other surgical management options for bullous keratopathy include Amniotic membrane grafting (AMG), annular keratotomy, anterior stromal puncture, and basement membrane polishing, among others.
EO2002, a first-in-class, non-surgical, magnetic cell-based therapy with the ability to modify disease, was developed by Emmecell through its exclusive Magnetic Cell Delivery (MCD) nanoparticle platform. It provides easier access to treatment before the disease becomes disabling and painful, and has the potential to prevent or delay the onset of more serious and invasive surgical procedures, including corneal transplantation. EO2002 is being evaluated in Phase I, a prospective, multicenter, open-label, dose-escalation study (EMME-01″) designed to assess the safety and tolerability of EO2002 with and without endothelial brushing (EB) or Descemet stripping (DS) in eyes with corneal edema secondary to corneal endothelial dysfunction that qualifies for surgery involving full-thickness corneal transplantation or endothelial keratoplasty.
Report Attribute
Details
Market Value in 2022
US$ 410 Million
Expected Market Value (2023)
US$ 427.54 Million
Anticipated Forecast Value (2033)
US$ 650 Million
Projected Growth Rate (2023 to 2033)
CAGR 4.3%
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
2017 to 2022 Bullous Keratopathy Demand Analysis vs. Forecast 2023 to 2033
The bullous keratopathy market was valued at US$ 410 Million in 2022 and expanded with a CAGR of 4.2% between 2018 and 2022. Rising cases of cataract surgeries and the advent of advanced technologies in corneal transplant and implant surgeries are proving to be game changers in market expansion. Considering these factors, the bullous Keratopathy market is expected to possess a valuation of US$ 650 Million, growing with a CAGR of 4.3%.
Which are Some Prominent Drivers of the Bullous Keratopathy market?
Complications from Cataract Surgeries augmenting Market Growth
Rising complications from cataract surgeries and glaucoma surgeries and the growing prevalence of eye disorders are driving the market of bullous keratopathy. Furthermore, the adoption of surgical management options for bullous keratopathy including Amniotic membrane grafting (AMG), annular keratotomy, anterior stromal puncture, basement membrane polishing, etc. is boosting the growth of this market. Cataract surgery remained the leading cause of endothelial dysfunction/bullous keratopathy (39.9%), followed by combined surgery (23.0%) and FED (11.1%). FED, Fuchs’ endothelial dystrophy.
Find your sweet spots for generating winning opportunities in this market.
What are the Challenges Projected to be Faced by the Market?
Increased risk factors of the surgery
Most people do well with bullous Keratopathy surgery. But complications can happen. Possible complications are Keratitis, perforation of the eye, extrusion of your ring, eye swelling, movement of your ring, night halos or glare, chronic eye pain, infections, etc. are expected to hamper the growth of the market during the forecast period. Furthermore, the high cost of ophthalmology devices and surgical procedures is anticipated to restrain the growth of this market during the forecast period.
Increase in risk of surgery failure
There is a risk that surgery might not correct the vision as much as expected. It might cause another vision problem like Astigmatism, where the curvature of the cornea becomes irregular. Some people who have corneal ring implantation may need an adjustment surgery to get a better outcome which will restrict the market growth.
Region-Wise Insights
What are the growth avenues for Bullous Keratopathy in North America?
Favorable Reimbursement policies driving the market
North America dominated the industry in 2021 and accounted for the largest share of around 59% of the overall revenue. Domicile of major market players, efficient reimbursement policies, and increasing Research and Development activities related to bullous Keratopathy are the factors expected to drive the region’s growth further.
North America's bullous keratopathy market was worth over US$ 190 Million in 2021. This is credited to the rising geriatric population base and the greater susceptibility of aging people to several chronic ailments, such as diabetes. Diabetic people are more prone to develop eye diseases that lead to vision loss. National Eye Institute estimates suggest that over 30,000 Americans undergo corneal transplants to replace injured and diseased corneas, creating numerous growth opportunities for the bullous Keratopathy market.
Surgical Incidences of Eye diseases to spur bullous keratopathy demand in Europe
Europe's bullous keratopathy market held over 19.1% business share in 2022 and is slated to record an appreciable target valuation by 2033. The regional industry is fuelled by the growing number of eye surgeries led by the prevalence of several eye disorders in Europe.
The increasing Research and Development investments and practices focused on developing advanced corneal implants will create favorable regional market statisticsfor the expansion of the bullous keratopathy market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category-Wise Insights
The hospital segment dominates the market with a revenue share of 58%
The hospital segment dominated the industry in 2021. The segment accounted for the largest revenue share of more than 58% with a revenue generation of US$ 150 Million in 2022 and is expected to register a lucrative CAGR over the forecast period.
The presence of highly skilled surgeons, the rising number of patients, and access to transnational eye banks are the factors anticipated to drive the segment growth.
Amniotic Membrane Grafting dominating in terms of Surgical Procedures
Amniotic membrane grafting segment accounts for the highest revenue share in the market. In this technique, first, the loose epithelium is removed with the help of a sponge or a blade. This results in a large epithelial defect, usually sparing the limbus. A required amniotic membrane is cut and placed over the cornea with the stromal side towards the cornea, which is sticky compared to the basement membrane. The AMG is then attached to the cornea with the help of interrupted stay sutures. If needed, a BCL can also be placed. Amniotic membrane transplantation is a successful adjunctive method in achieving corneal epithelization which will propel the growth of this segment during the forecast period.
Anti-Glaucoma Drugs lead the market for the postoperative period
These drugs are the most prevalent in primary medical management procedures. The drugs commonly employed are beta-blockers and alpha agonists-these work by reducing intraocular pressure, which reduces corneal edema and thickness in the postoperative period. Miotics and prostaglandins are avoided because they usually aggravate inflammation. Carbonic anhydrase inhibitors are also avoided as they are epitheliotoxic.
Start-ups in Bullous Keratopathy Market
Founded in 2015, Cellusion is a Japan-based Developer of iPS cell-based regenerative technology for bullous keratopathy. The regenerative material is developed by using iPS cell-derived cell transplantation for corneal endothelium replacement. The iPS cells are injected into the cornea for treating bullous keratopathy. It received funding of USD 14.7 million from Toyo Seikan Kaisha, UTEC, and 5 more.
Founded in 2016, Allotex is a Zurich, Switzerland-based company that is developing therapeutic solutions for the treatment of presbyopia, hyperopia, myopia, and astigmatism. The therapy is based on tissue addition technology that utilizes precisely-shaped human corneal allografts to create contact lenses or lens inserts. The corneal allografts can be placed on top of or just under Bowman’s (no need to place them deep in the cornea). It can be made in any shape, diameter, and thickness.
Market Competition
Key players in the Bullous Keratopathy market are- Hoffmann-La Roche Ltd, Regeneron, Pharmaceuticals, Inc., Pfizer, Inc., Bayer AG, Cellusion, CRSTEurope, Barraquer Eye Hospital, Planchard Eye & Laser Center, and Medscape. Some recent developments in the bullous keratopathy market are:
In September 2022: Celregen and Cellusion Inc. signed an exclusive license agreement for corneal endothelial cell regenerative therapy in Greater China.
In July 2022: Carl Zeiss Meditec and Precise Bio announced a partnership in the development and commercialization of tissue-based implants for ophthalmology.
Report Scope
Report Attribute
Details
Market Value in 2023
US$ 427.54 Million
Market Value in 2033
US$ 650 Million
Growth Rate
CAGR of 4.3% from 2023 to 2033
Base Year for Estimation
2022
Historical Data
2018 to 2022
Forecast Period
2023 to 2033
Quantitative Units
Revenue in US$ Million and CAGR from 2023 to 2033
Report Coverage
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
Therapies
Treatment
End Users
Region
Regions Covered
North America
Latin America
Europe
South Asia & Pacific
East Asia
Middle East & Africa
Key Countries Profiled
USA
Canada
Brazil
Mexico
Mexico
Germany
UK
France
Spain
Italy
India
Malaysia
Singapore
Thailand
China
Japan
South Korea
Australia
New Zealand
GCC countries
South Africa
Israel
Key Companies Profiled
Hoffmann-La Roche Ltd
Regeneron Pharmaceuticals
Pfizer Inc.
Bayer AG
Cellusion
CRSTEurope
Barraquer Eye Hospital
Planchard Eye & Laser Center
Medscape
Customization
Available Upon Request
Key Segments Profiled in the Bullous Keratopathy Market Industry Survey
Bullous Keratopathy Market by Therapies:
Emmecell
Drug Description
Regulatory Milestones
Safety and Efficiency
Product Profile
Cellusion
Drug Description
Other Development Activities
Clinical Development
Safety and Efficiency
Product Profile
Bullous Keratopathy Market by End User:
Hospitals
Surgical Centers
Bullous Keratopathy Market by Treatment:
Medical Management
Lubricants
Steroids
Hyperosmotic agents
Anti- Glaucoma drugs
Antibiotics
Amniotic Membrane Grafting (AMG)
Annular Keratotomy
Anterior Stromal Puncture
Bullous Keratopathy Market by Region:
North America
Latin America
Europe
South Asia & Pacific
East Asia
Middle East & Africa
Frequently Asked Questions
What is the anticipated growth of the Bullous Keratopathy market until 2033?
FMI projects the global Bullous Keratopathy market to expand at a 4.3% value CAGR by 2033.
What is the estimated market value of the Bullous Keratopathy market expected in 2022?
The global Bullous Keratopathy market is estimated at a market value of US$ 410 Million in 2022.
What is the estimated market value of the Bullous Keratopathy market expected in 2033?
The global Bullous Keratopathy market is expected to garner a market value of US$ 650 Million by 2033.
Which region is forecast to be the most lucrative for Bullous Keratopathy market growth?
FMI has projected North America to be one of the most profitable regions for the Bullous Keratopathy market.
Table of Content
1. Executive Summary | Bullous Keratopathy Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033
5.3.1. Medical Management
5.3.1.1. Lubricants
5.3.1.2. Steroids
5.3.1.3. Hyperosmotic Agents
5.3.1.4. Anti-Glaucoma Drugs
5.3.1.5. Antibiotics
5.3.2. Surgical Management
5.3.2.1. AMillioniotic Membrane Grafting (AMG)
5.3.2.2. Annular Keratotomy
5.3.2.3. Anterior Stromal Puncture
5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033
6. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapies
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Therapies, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapies, 2023 to 2033
6.3.1. Emmecell
6.3.1.1. Drug Description
6.3.1.2. Regulatory Milestones
6.3.1.3. Safety and Efficacy
6.3.1.4. Product Profile
6.3.2. Cellusion
6.3.2.1. Drug Description
6.3.2.2. Clinical Development
6.3.2.3. Other Development Activities
6.3.2.4. Safety and Efficacy
6.3.2.5. Product Profile
6.4. Y-o-Y Growth Trend Analysis By Therapies, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Therapies, 2023 to 2033
7. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Users
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By End Users, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End Users, 2023 to 2033
7.3.1. Hospitals
7.3.2. Surgical Centers
7.4. Y-o-Y Growth Trend Analysis By End Users, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By End Users, 2023 to 2033
8. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. South Asia & Pacific
8.3.5. East Asia
8.3.6. Middle East and Africa (MEA)
8.4. Market Attractiveness Analysis By Region
9. North America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. United States of America
9.2.1.2. Canada
9.2.2. By Treatment
9.2.3. By Therapies
9.2.4. By End Users
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Treatment
9.3.3. By Therapies
9.3.4. By End Users
9.4. Key Takeaways
10. Latin America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Treatment
10.2.3. By Therapies
10.2.4. By End Users
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Treatment
10.3.3. By Therapies
10.3.4. By End Users
10.4. Key Takeaways
11. Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United Kingdom
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Treatment
11.2.3. By Therapies
11.2.4. By End Users
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Treatment
11.3.3. By Therapies
11.3.4. By End Users
11.4. Key Takeaways
12. South Asia & Pacific Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Malaysia
12.2.1.3. Singapore
12.2.1.4. Thailand
12.2.1.5. Australia
12.2.1.6. New Zealand
12.2.1.7. Rest of South Asia & Pacific
12.2.2. By Treatment
12.2.3. By Therapies
12.2.4. By End Users
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Treatment
12.3.3. By Therapies
12.3.4. By End Users
12.4. Key Takeaways
13. East Asia Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Treatment
13.2.3. By Therapies
13.2.4. By End Users
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Treatment
13.3.3. By Therapies
13.3.4. By End Users
13.4. Key Takeaways
14. MEA Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MEA
14.2.2. By Treatment
14.2.3. By Therapies
14.2.4. By End Users
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Treatment
14.3.3. By Therapies
14.3.4. By End Users
14.4. Key Takeaways
15. Key Countries Analysis
15.1. United States of America
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2022
15.1.2.1. By Treatment
15.1.2.2. By Therapies
15.1.2.3. By End Users
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2022
15.2.2.1. By Treatment
15.2.2.2. By Therapies
15.2.2.3. By End Users
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2022
15.3.2.1. By Treatment
15.3.2.2. By Therapies
15.3.2.3. By End Users
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2022
15.4.2.1. By Treatment
15.4.2.2. By Therapies
15.4.2.3. By End Users
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2022
15.5.2.1. By Treatment
15.5.2.2. By Therapies
15.5.2.3. By End Users
15.6. United Kingdom
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2022
15.6.2.1. By Treatment
15.6.2.2. By Therapies
15.6.2.3. By End Users
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2022
15.7.2.1. By Treatment
15.7.2.2. By Therapies
15.7.2.3. By End Users
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2022
15.8.2.1. By Treatment
15.8.2.2. By Therapies
15.8.2.3. By End Users
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2022
15.9.2.1. By Treatment
15.9.2.2. By Therapies
15.9.2.3. By End Users
15.10. India
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2022
15.10.2.1. By Treatment
15.10.2.2. By Therapies
15.10.2.3. By End Users
15.11. Malaysia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2022
15.11.2.1. By Treatment
15.11.2.2. By Therapies
15.11.2.3. By End Users
15.12. Singapore
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2022
15.12.2.1. By Treatment
15.12.2.2. By Therapies
15.12.2.3. By End Users
15.13. Thailand
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2022
15.13.2.1. By Treatment
15.13.2.2. By Therapies
15.13.2.3. By End Users
15.14. Australia
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2022
15.14.2.1. By Treatment
15.14.2.2. By Therapies
15.14.2.3. By End Users
15.15. New Zealand
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2022
15.15.2.1. By Treatment
15.15.2.2. By Therapies
15.15.2.3. By End Users
15.16. China
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2022
15.16.2.1. By Treatment
15.16.2.2. By Therapies
15.16.2.3. By End Users
15.17. Japan
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2022
15.17.2.1. By Treatment
15.17.2.2. By Therapies
15.17.2.3. By End Users
15.18. South Korea
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2022
15.18.2.1. By Treatment
15.18.2.2. By Therapies
15.18.2.3. By End Users
15.19. GCC Countries
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2022
15.19.2.1. By Treatment
15.19.2.2. By Therapies
15.19.2.3. By End Users
15.20. South Africa
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2022
15.20.2.1. By Treatment
15.20.2.2. By Therapies
15.20.2.3. By End Users
15.21. Israel
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2022
15.21.2.1. By Treatment
15.21.2.2. By Therapies
15.21.2.3. By End Users
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Treatment
16.3.3. By Therapies
16.3.4. By End Users
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Hoffmann-La Roche Ltd.,
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. Regeneron
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. Pfizer, Inc.,
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. Bayer AG
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. Cellusion
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. CRSTEurope
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. Barraquer Eye Hospital
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. Planchard Eye & Laser Center
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. Medscape
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. Eyewiki
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
18. Assumptions & Acronyms Used19. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 3: Global Value (US$ Million) Forecast by Therapies, 2018 to 2033
Table 4: Global Value (US$ Million) Forecast by End Users, 2018 to 2033
Table 5: North America Value (US$ Million) Forecast by Country, 2018 to 2033
Table 6: North America Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 7: North America Value (US$ Million) Forecast by Therapies, 2018 to 2033
Table 8: North America Value (US$ Million) Forecast by End Users, 2018 to 2033
Table 9: Latin America Value (US$ Million) Forecast by Country, 2018 to 2033
Table 10: Latin America Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 11: Latin America Value (US$ Million) Forecast by Therapies, 2018 to 2033
Table 12: Latin America Value (US$ Million) Forecast by End Users, 2018 to 2033
Table 13: Europe Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Europe Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 15: Europe Value (US$ Million) Forecast by Therapies, 2018 to 2033
Table 16: Europe Value (US$ Million) Forecast by End Users, 2018 to 2033
Table 17: South Asia & Pacific Value (US$ Million) Forecast by Country, 2018 to 2033
Table 18: South Asia & Pacific Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 19: South Asia & Pacific Value (US$ Million) Forecast by Therapies, 2018 to 2033
Table 20: South Asia & Pacific Value (US$ Million) Forecast by End Users, 2018 to 2033
Table 21: East Asia Value (US$ Million) Forecast by Country, 2018 to 2033
Table 22: East Asia Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 23: East Asia Value (US$ Million) Forecast by Therapies, 2018 to 2033
Table 24: East Asia Value (US$ Million) Forecast by End Users, 2018 to 2033
Table 25: MEA Value (US$ Million) Forecast by Country, 2018 to 2033
Table 26: MEA Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 27: MEA Value (US$ Million) Forecast by Therapies, 2018 to 2033
Table 28: MEA Value (US$ Million) Forecast by End Users, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Value (US$ Million) by Treatment, 2023 to 2033
Figure 2: Global Value (US$ Million) by Therapies, 2023 to 2033
Figure 3: Global Value (US$ Million) by End Users, 2023 to 2033
Figure 4: Global Value (US$ Million) by Region, 2023 to 2033
Figure 5: Global Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 6: Global Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 7: Global Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 8: Global Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 9: Global Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 10: Global Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 11: Global Value (US$ Million) Analysis by Therapies, 2018 to 2033
Figure 12: Global Value Share (%) and BPS Analysis by Therapies, 2023 to 2033
Figure 13: Global Y-o-Y Growth (%) Projections by Therapies, 2023 to 2033
Figure 14: Global Value (US$ Million) Analysis by End Users, 2018 to 2033
Figure 15: Global Value Share (%) and BPS Analysis by End Users, 2023 to 2033
Figure 16: Global Y-o-Y Growth (%) Projections by End Users, 2023 to 2033
Figure 17: Global Attractiveness by Treatment, 2023 to 2033
Figure 18: Global Attractiveness by Therapies, 2023 to 2033
Figure 19: Global Attractiveness by End Users, 2023 to 2033
Figure 20: Global Attractiveness by Region, 2023 to 2033
Figure 21: North America Value (US$ Million) by Treatment, 2023 to 2033
Figure 22: North America Value (US$ Million) by Therapies, 2023 to 2033
Figure 23: North America Value (US$ Million) by End Users, 2023 to 2033
Figure 24: North America Value (US$ Million) by Country, 2023 to 2033
Figure 25: North America Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 26: North America Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 27: North America Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 28: North America Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 29: North America Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 30: North America Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 31: North America Value (US$ Million) Analysis by Therapies, 2018 to 2033
Figure 32: North America Value Share (%) and BPS Analysis by Therapies, 2023 to 2033
Figure 33: North America Y-o-Y Growth (%) Projections by Therapies, 2023 to 2033
Figure 34: North America Value (US$ Million) Analysis by End Users, 2018 to 2033
Figure 35: North America Value Share (%) and BPS Analysis by End Users, 2023 to 2033
Figure 36: North America Y-o-Y Growth (%) Projections by End Users, 2023 to 2033
Figure 37: North America Attractiveness by Treatment, 2023 to 2033
Figure 38: North America Attractiveness by Therapies, 2023 to 2033
Figure 39: North America Attractiveness by End Users, 2023 to 2033
Figure 40: North America Attractiveness by Country, 2023 to 2033
Figure 41: Latin America Value (US$ Million) by Treatment, 2023 to 2033
Figure 42: Latin America Value (US$ Million) by Therapies, 2023 to 2033
Figure 43: Latin America Value (US$ Million) by End Users, 2023 to 2033
Figure 44: Latin America Value (US$ Million) by Country, 2023 to 2033
Figure 45: Latin America Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 46: Latin America Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 47: Latin America Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 48: Latin America Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 49: Latin America Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 50: Latin America Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 51: Latin America Value (US$ Million) Analysis by Therapies, 2018 to 2033
Figure 52: Latin America Value Share (%) and BPS Analysis by Therapies, 2023 to 2033
Figure 53: Latin America Y-o-Y Growth (%) Projections by Therapies, 2023 to 2033
Figure 54: Latin America Value (US$ Million) Analysis by End Users, 2018 to 2033
Figure 55: Latin America Value Share (%) and BPS Analysis by End Users, 2023 to 2033
Figure 56: Latin America Y-o-Y Growth (%) Projections by End Users, 2023 to 2033
Figure 57: Latin America Attractiveness by Treatment, 2023 to 2033
Figure 58: Latin America Attractiveness by Therapies, 2023 to 2033
Figure 59: Latin America Attractiveness by End Users, 2023 to 2033
Figure 60: Latin America Attractiveness by Country, 2023 to 2033
Figure 61: Europe Value (US$ Million) by Treatment, 2023 to 2033
Figure 62: Europe Value (US$ Million) by Therapies, 2023 to 2033
Figure 63: Europe Value (US$ Million) by End Users, 2023 to 2033
Figure 64: Europe Value (US$ Million) by Country, 2023 to 2033
Figure 65: Europe Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 66: Europe Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 67: Europe Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 68: Europe Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 69: Europe Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 70: Europe Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 71: Europe Value (US$ Million) Analysis by Therapies, 2018 to 2033
Figure 72: Europe Value Share (%) and BPS Analysis by Therapies, 2023 to 2033
Figure 73: Europe Y-o-Y Growth (%) Projections by Therapies, 2023 to 2033
Figure 74: Europe Value (US$ Million) Analysis by End Users, 2018 to 2033
Figure 75: Europe Value Share (%) and BPS Analysis by End Users, 2023 to 2033
Figure 76: Europe Y-o-Y Growth (%) Projections by End Users, 2023 to 2033
Figure 77: Europe Attractiveness by Treatment, 2023 to 2033
Figure 78: Europe Attractiveness by Therapies, 2023 to 2033
Figure 79: Europe Attractiveness by End Users, 2023 to 2033
Figure 80: Europe Attractiveness by Country, 2023 to 2033
Figure 81: South Asia & Pacific Value (US$ Million) by Treatment, 2023 to 2033
Figure 82: South Asia & Pacific Value (US$ Million) by Therapies, 2023 to 2033
Figure 83: South Asia & Pacific Value (US$ Million) by End Users, 2023 to 2033
Figure 84: South Asia & Pacific Value (US$ Million) by Country, 2023 to 2033
Figure 85: South Asia & Pacific Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 86: South Asia & Pacific Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 87: South Asia & Pacific Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 88: South Asia & Pacific Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 89: South Asia & Pacific Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 90: South Asia & Pacific Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 91: South Asia & Pacific Value (US$ Million) Analysis by Therapies, 2018 to 2033
Figure 92: South Asia & Pacific Value Share (%) and BPS Analysis by Therapies, 2023 to 2033
Figure 93: South Asia & Pacific Y-o-Y Growth (%) Projections by Therapies, 2023 to 2033
Figure 94: South Asia & Pacific Value (US$ Million) Analysis by End Users, 2018 to 2033
Figure 95: South Asia & Pacific Value Share (%) and BPS Analysis by End Users, 2023 to 2033
Figure 96: South Asia & Pacific Y-o-Y Growth (%) Projections by End Users, 2023 to 2033
Figure 97: South Asia & Pacific Attractiveness by Treatment, 2023 to 2033
Figure 98: South Asia & Pacific Attractiveness by Therapies, 2023 to 2033
Figure 99: South Asia & Pacific Attractiveness by End Users, 2023 to 2033
Figure 100: South Asia & Pacific Attractiveness by Country, 2023 to 2033
Figure 101: East Asia Value (US$ Million) by Treatment, 2023 to 2033
Figure 102: East Asia Value (US$ Million) by Therapies, 2023 to 2033
Figure 103: East Asia Value (US$ Million) by End Users, 2023 to 2033
Figure 104: East Asia Value (US$ Million) by Country, 2023 to 2033
Figure 105: East Asia Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 106: East Asia Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 107: East Asia Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 108: East Asia Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 109: East Asia Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 110: East Asia Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 111: East Asia Value (US$ Million) Analysis by Therapies, 2018 to 2033
Figure 112: East Asia Value Share (%) and BPS Analysis by Therapies, 2023 to 2033
Figure 113: East Asia Y-o-Y Growth (%) Projections by Therapies, 2023 to 2033
Figure 114: East Asia Value (US$ Million) Analysis by End Users, 2018 to 2033
Figure 115: East Asia Value Share (%) and BPS Analysis by End Users, 2023 to 2033
Figure 116: East Asia Y-o-Y Growth (%) Projections by End Users, 2023 to 2033
Figure 117: East Asia Attractiveness by Treatment, 2023 to 2033
Figure 118: East Asia Attractiveness by Therapies, 2023 to 2033
Figure 119: East Asia Attractiveness by End Users, 2023 to 2033
Figure 120: East Asia Attractiveness by Country, 2023 to 2033
Figure 121: MEA Value (US$ Million) by Treatment, 2023 to 2033
Figure 122: MEA Value (US$ Million) by Therapies, 2023 to 2033
Figure 123: MEA Value (US$ Million) by End Users, 2023 to 2033
Figure 124: MEA Value (US$ Million) by Country, 2023 to 2033
Figure 125: MEA Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 126: MEA Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 127: MEA Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 128: MEA Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 129: MEA Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 130: MEA Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 131: MEA Value (US$ Million) Analysis by Therapies, 2018 to 2033
Figure 132: MEA Value Share (%) and BPS Analysis by Therapies, 2023 to 2033
Figure 133: MEA Y-o-Y Growth (%) Projections by Therapies, 2023 to 2033
Figure 134: MEA Value (US$ Million) Analysis by End Users, 2018 to 2033
Figure 135: MEA Value Share (%) and BPS Analysis by End Users, 2023 to 2033
Figure 136: MEA Y-o-Y Growth (%) Projections by End Users, 2023 to 2033
Figure 137: MEA Attractiveness by Treatment, 2023 to 2033
Figure 138: MEA Attractiveness by Therapies, 2023 to 2033
Figure 139: MEA Attractiveness by End Users, 2023 to 2033
Figure 140: MEA Attractiveness by Country, 2023 to 2033
